Shareholders in Exagen (NASDAQ:XGN) Have Lost 84%, as Stock Drops 12% This Past Week
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
Bears Are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations
Exagen Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Increased Its FY24 Revenue Outlook Above Estimates.
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 38% Share Price Rise